EU CSDR definition

EU CSDR means Regulation (EU) No. 909/2014 of the European Parliament and of the Council of 23 July 2014, as amended from time to time.
Sample 1Sample 2Sample 3

Examples of EU CSDR in a sentence

  • More information on the EU CSDR Settlement Discipline Regime can be found in the MarketGuide - EU CSDR: Settlement Discipline, published at www.six-group.com > Login> Securities Service Private > MarketGuide > Country Information > Further Market Information > EU CSDR Settlement Discipline.

  • If, in relation to an ASP and a business day, the aggregate amount of EU CSDR Cash Penalties that the Clearing House determines is payable by it to EquityClear Clearing Members exceeds the aggregate amount of EU CSDR Cash Penalties it determines is payable from EquityClear Clearing Members to it, the Clearing House may recover such loss from all EquityClear Clearing Members on a pro rata basis as an additional fee for the EquityClear service.

  • The Clearing House may collect and distribute EU CSDR Cash Penalties, in respect of failed settlement instructions submitted to an ASP, to and from the relevant EquityClear Clearing Members.

  • For repos against collateral that includes a transferable security regulated under the EU MiFID and that have been traded or which it is possible to trade on a MiFIR-regulated trading venue (regulated market, multilateral trading facility or organised trading facility), which are subject to the settlement requirements of the EU CSDR, forward-forward repos are defined for the purposes of this survey as contracts with a purchase date of Monday, December 13, 2021, or later.

  • For repos against collateral that includes a transferable security regulated under the EU MiFID and that have been traded or which it is possible to trade on a MiFIR-regulated trading venue (regulated market, multilateral trading facility or organised trading facility), which are subject to the settlement requirements of the EU CSDR, forward-forward repos are defined for the purposes of this survey as contracts with a purchase date of Monday, December 12, 2022, or later.

  • This report summarises the main areas under review to ensure fulfilment of the objectives of the EU CSDR in a more proportionate, efficient and effective manner.

  • This requirement will also apply to any third country CSD benefiting at the point of exit from the transitional under the EU CSDR or the 2017 regulations.

  • For repos against collateral that includes a transferable security regulated under the EU MiFID and that have been traded or which it is possible to trade on a MiFIR-regulated trading venue (regulated market, multilateral trading facility or organised trading facility), which are subject to the settlement requirements of the EU CSDR, forward-forward repos are defined for the purposes of this survey as contracts with a purchase date of Monday, June 14, 2021, or later.

  • The ECSDA Framework (market practice) applies to all CSDs subject to the EU CSDR (text with EEA relevance) or alike regulation7.

  • For repos against collateral that includes a transferable security regulated under the EU MiFID and that have been traded or which it is possible to trade on a MiFIR-regulated trading venue (regulated market, multilateral trading facility or organised trading facility), which are subject to the settlement requirements of the EU CSDR, forward-forward repos are defined for the purposes of this survey as contracts with a purchase date of Monday, June 13, 2022, or later.

Related to EU CSDR

  • EUA or “Extended Use Agreement” means, with respect to the HC Program, an agreement which sets forth the set-aside requirements and other Development requirements under the HC Program.

  • EUWA means the European Union (Withdrawal) Act 2018;

  • Phase 3 Clinical Trial means a pivotal clinical trial in humans performed to gain evidence with statistical significance of the efficacy of a product in a target population, and to obtain expanded evidence of safety for such product that is needed to evaluate the overall benefit-risk relationship of such product, to form the basis for approval of an NDA and to provide an adequate basis for physician labeling, as described in 21 C.F.R. § 312.21(c) or the corresponding regulation in jurisdictions other than the United States.

  • Phase 2 Clinical Trial means a human clinical trial, for which the primary endpoints include a determination of dose ranges or an indication of efficacy in patients being studied as described in 21 C.F.R. §312.21(b), or an equivalent clinical trial in a country in the Territory other than the United States.

  • Clinical review criteria means the written screening procedures, decision abstracts, clinical protocols, and practice guidelines used by a health carrier to determine the necessity and appropriateness of health care services.

  • ug/l means micrograms per liter.